ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.053 AUD -1.85% Market Closed
Market Cap: 107.2m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

ImpediMed Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ImpediMed Ltd
Cost of Revenue Peer Comparison

Comparables:
R
RSH
C
CYC
COH
OIL
EMV

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ImpediMed Ltd
ASX:IPD
Cost of Revenue
-AU$1.3m
CAGR 3-Years
6%
CAGR 5-Years
-1%
CAGR 10-Years
-3%
R
Respiri Ltd
ASX:RSH
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cyclopharm Ltd
ASX:CYC
Cost of Revenue
-AU$10.2m
CAGR 3-Years
-29%
CAGR 5-Years
-30%
CAGR 10-Years
-10%
Cochlear Ltd
ASX:COH
Cost of Revenue
-AU$540.1m
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Optiscan Imaging Ltd
ASX:OIL
Cost of Revenue
-AU$526.2k
CAGR 3-Years
20%
CAGR 5-Years
14%
CAGR 10-Years
-29%
EMvision Medical Devices Ltd
ASX:EMV
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is ImpediMed Ltd's Cost of Revenue?
Cost of Revenue
-1.3m AUD

Based on the financial report for Jun 30, 2024, ImpediMed Ltd's Cost of Revenue amounts to -1.3m AUD.

What is ImpediMed Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%

Over the last year, the Cost of Revenue growth was 15%. The average annual Cost of Revenue growth rates for ImpediMed Ltd have been 6% over the past three years , -1% over the past five years , and -3% over the past ten years .

Back to Top